ALS news

Latest news

• Coya completes enrollment in ALS trial, data due early Q2 2027 (opens in a new tab)

  Investing.com UK · Oct 5, 2026

• Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS (opens in a new tab)

  Business Wire · Oct 5, 2026

• ALS Ltd BlackRock Group Ceases to Be Substantial Holder (opens in a new tab)

  kalkine.com.au · Oct 4, 2026

• How Are Foraco International (TSX:FAR), Altius Minerals (TSX:ALS) and Lithium Americas (TSX:LAC) Connected to Lithium? (opens in a new tab)

  kalkinemedia.com · Oct 2, 2026

• Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision (opens in a new tab)

  TradingView · Oct 2, 2026

• BlackRock Group Ceases to Be Substantial Shareholder in ALS Ltd (opens in a new tab)

  The Globe and Mail · Oct 1, 2026

• DT on the Bombers: Another Als upset? (opens in a new tab)

  Global News · Oct 1, 2026

• ExxonMobil und TotalEnergies gehen als Gewinner der brasilianischen Spot-Ölauktion hervor (opens in a new tab)

  TradingView · Oct 1, 2026

• Former NFL Player Steve Gleason Turns to Music with Empowering New Project During 15-Year Fight Against ALS (opens in a new tab)

  People.com · Oct 1, 2026

• Viral infections can accelerate the progression of ALS, McMaster researchers find (opens in a new tab)

  McMaster News · Oct 1, 2026

• ALS Limited (ASX:ALQ): FY26 Earnings Growth, Lower Debt and FY27 Priorities (opens in a new tab)

  kalkine.com.au · Oct 1, 2026

• Viral Infections Can Accelerate the Progression of ALS, McMaster Researchers Find | Newswise (opens in a new tab)

  Newswise · Oct 1, 2026

• VectorY broadens global PIONEER-ALS clinical trial cohort (opens in a new tab)

  Clinical Trials Arena · Sep 30, 2026

• How HIV Inspired Drug Development for ALS (opens in a new tab)

  Technology Networks · Sep 30, 2026

• I AM ALS COMMUNITY POWERS HISTORIC REAUTHORIZATION OF ACT FOR ALS (opens in a new tab)

  PR Newswire · Sep 29, 2026

• New AI app helps people with ALS keep their own voices (opens in a new tab)

  alsnewstoday.com · Sep 29, 2026

• Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial (opens in a new tab)

  Proactive financial news · Sep 29, 2026

• Nasal spray antibody trialled in early-stage ALS patients (opens in a new tab)

  nrtimes.co.uk · Sep 29, 2026

• VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size (opens in a new tab)

  Business Wire · Sep 29, 2026

• How minerals testing demand is reshaping earnings at S&P/ASX 200 laboratory group ALS Limited (ASX: ALQ) (opens in a new tab)

  Kalkine · Sep 29, 2026

• ACT for ALS Reauthorization Advances to the President After Today’s Senate Action (opens in a new tab)

  mda.org · Sep 28, 2026

• Robert Earl Keen’s Longtime Guitarist Received an ALS Diagnosis. Texas Music Is Rallying (opens in a new tab)

  Rolling Stone · Sep 28, 2026

• NeuroSense CFO to discuss ALS drug PrimeC progr... (opens in a new tab)

  Pluang · Sep 28, 2026

• Altius Minerals (TSX:ALS), Why Is It Drawing Fresh Attention? (opens in a new tab)

  Yahoo Finance · Sep 28, 2026

• Sola Biosciences Japan Nabs ¥6B Grant to Advance ALS Gene Therapy (opens in a new tab)

  Genome Web · Sep 28, 2026

• Tiziana doses first three patients in ALS trial of nasal antibody foralumab (opens in a new tab)

  Yahoo Finance · Sep 28, 2026

• Japan AMED grant supports Sola’s SOL-257 for ALS (opens in a new tab)

  bioworld.com · Sep 28, 2026

• Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab (opens in a new tab)

  The Manila Times · Sep 28, 2026

• ALS Limited (ASX:ALQ) Operates DRP for Final Dividend With Shares Acquired On Market (opens in a new tab)

  Kalkine · Sep 28, 2026

• What Makes ALS (ASX:ALQ) Stand Out in Its Latest Update? (opens in a new tab)

  kalkinemedia.com · Sep 28, 2026